SCHEMBL1582004

SCHEMBL1582004

CCOC(=O)/C(=C\CC1CCCC1)c1ccc(S(C)(=O)=O)s1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.34
KMT2A Q03164 2/20 0.34
GAA P10253 1/20 0.34
TSHR P16473 1/20 0.34
PSEN1 P49768 1/20 0.33
PSEN2 P49810 1/20 0.33
APH1B Q8WW43 1/20 0.33
NCSTN Q92542 1/20 0.33
APH1A Q96BI3 1/20 0.33
PSENEN Q9NZ42 1/20 0.33
NR3C1 P04150 1/20 0.33
AR P10275 1/20 0.33
LMNA P02545 3/20 0.32
PPARG P37231 1/20 0.32
NCOA2 Q15596 1/20 0.32
NCOA1 Q15788 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
NCOA3 Q9Y6Q9 1/20 0.32
L3MBTL1 Q9Y468 3/20 0.31
TDP1 Q9NUW8 3/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1582003 1.00 ALDH1A1 (0.34) ALDH1A1KMT2AGAATSHRPSEN1
SCHEMBL1582006 1.00 ALDH1A1 (0.34) ALDH1A1KMT2AGAATSHRPSEN1
SCHEMBL1582340 0.81 NR1D1 (0.41) ALDH1A1KMT2ATSHRNR3C1AR
SCHEMBL1582342 0.81 NR1D1 (0.41) ALDH1A1KMT2ATSHRNR3C1AR
SCHEMBL1582344 0.81 NR1D1 (0.41) ALDH1A1KMT2ATSHRNR3C1AR
SCHEMBL1581391 0.77 KMT2A (0.44) ALDH1A1KMT2ALMNAPOLBMEN1
SCHEMBL1581394 0.77 KMT2A (0.44) ALDH1A1KMT2ALMNAPOLBMEN1
SCHEMBL1581797 0.76 DRD2 (0.33) ALDH1A1KMT2ALMNAPPARGNCOA2
SCHEMBL1581795 0.76 DRD2 (0.33) ALDH1A1KMT2ALMNAPPARGNCOA2
SCHEMBL1581799 0.76 DRD2 (0.33) ALDH1A1KMT2ALMNAPPARGNCOA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1585739-B1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS LILLY CO ELI (US) 2011-04-20 EP disclosed
US-7576108-B2 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
US-20060111353-A1 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY 2006-05-25 US disclosed
EP-1585739-A1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS ELI LILLY AND COMPANY (US) 2005-10-19 EP disclosed
WO-2004063179-A1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS ELI LILLY AND COMPANY (US) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111353-A1 Substituted arylcyclopropylacetamides as glucokinase activators GCK, GCKR, GALK1 ALDH1A1 510/4885KMT2A 1603/4885GAA 81/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.